Royalty Pharma plc (RPRX)

Royalty Pharma plc records an AlphaScore of 51/100 in the Healthcare sector, trading at $56.93 with a market cap of $32.90 billion. Key metrics feature a net margin of 32.42% and an exceptional gross margin of 95.82%. A primary strength is the outstanding gross margin of 95.82% and a high momentum sub-score of 77. A significant risk is the forward P/E context versus a debt-to-equity ratio of 0.92 and slow growth sub-score of 14. Evidence is limited to the provided snapshot data from 2026-10-11.

Written 11/10/2026, 00:33:30 UTC · Snapshot 11/10/2026